Takeda, Schering Sue Teva For Integrilin Patent Infringement
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceuticals and Schering-Plough filed suit in a U.S. Court against Israel's Teva Pharmaceutical Industries, alleging patent infringement. Takeda's Millennium and Schering sought an injunction against Teva's filing for U.S. FDA approval of its generic of the plaintiffs' Integrilin (eptifibatide) injection produced from rattlesnake venom as an anti-clotting drug. Takeda and Schering say Mellennium's U.S. patent on the drug is good until 2015. (Click here for more